Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemlapodect - Noema Pharma

Next Previous
X
Search
Drug Profile

Gemlapodect - Noema Pharma

Alternative Names: NOE-105

Latest Information Update: 13 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Noema Pharma
  • Class Behavioural disorder therapies; Small molecules
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gilles de la Tourette's syndrome; Speech disorders

Most Recent Events

  • 06 Aug 2024 Phase-II clinical trials in Gilles de la Tourette's syndrome (In adolescents, In adults) in Spain (PO) (NCT06315751)
  • 18 Mar 2024 Noema Pharma plans a phase II trial for Gilles de la Tourette's syndrome (In adolescents, In adults, In the elderly) (PO, Capsule), in May 2024 (NCT06315751)
  • 24 Nov 2023 Noema Pharma AG completes phase IIb clinical trial in Speech disorders in Australia and US (PO, Capsule) (NCT05583955)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top